瑞桑基祖马布作为治疗方法用于反复性皮肤性性
Alessandra Michelucci1, Flavia Manzo Margiotta, Giammarco Granieri
1In the Department of Dermatology, University of Pisa, Italy, Alessandra Michelucci, MD; Flavia Manzo Margiotta, MD; Giammarco Granieri, MD; Giorgia Salvia, MD; Cristian Fidanzi, MD; and Matteo Bevilacqua, MD, are Dermatology Residents; Salvatore Panduri, MD, is Specialized Physician; Marco Romanelli, MD, PhD, is Full Professor; and Valentina Dini, MD, PhD, is Associate Professor. Acknowledgments: This manuscript describes off-label product use: risankizumab for pyoderma gangrenosum. The authors have disclosed no financial relationships related to this article. Submitted January 13, 2023; accepted in revised form June 23, 2023.
瑞桑基苏马布是一种抗联素-23单克隆抗体 (mAb),有效地治疗了两例复杂的皮肤质性 (PG) 病例. 这种疗法与局部伤口护理相结合,在治疗耐火性PG时表现出有效性和安全性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 皮肤病 (Pyoderma gangrenosum,简称PG) 是一种具有挑战性的中性恋性皮肤病.
- 目前的治疗包括皮质类固醇和免疫抑制剂,新兴的研究涉及单克隆抗体 (mAbs).
研究的目的:
- 评价抗干白素-23 mAb的risankizumab在管理复杂的皮肤质性病例中的有效性和安全性.
主要方法:
- 两名耐火性PG患者在现有免疫抑制疗法之外接受了非标签的risankizumab (150毫克皮下注射).
- 治疗包括基于TIME原则的局部管理.
- 剂量:初始,第4周,然后每10周.
主要成果:
- 在第24周 (患者1) 和第16周 (患者2) 实现完整的临床康复.
- 缓解持续到第40周,没有副作用或复发.
- 瑞桑基祖马布在多重耐火性PG的证明有效性和安全性.
结论:
- 瑞桑基祖马布是一种可行的治疗选择,用于复杂的,耐治疗的皮肤病.
- 与个性化的局部伤口护理相结合,可以提高治疗结果.
- 对PG管理的mAbs进行进一步的研究是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...


